Navigation Links
GeNO LLC Initiates Phase 2 Trial For Nitric Oxide Delivery System
Date:12/8/2010

ward in our plans for these novel technologies, Phase 2 testing of the NITROSYL systems in patients is an important milestone for GeNO," said GeNO LLC Founder and President David Fine. "As a clinical-stage organization, this trial not only moves the in-hospital solution forward but also enables us to move our other exciting, patent-protected technologies, such as the GeNO Ambulatory NITROSYL System, towards clinical development as well."

Robert F. Roscigno, PhD, Vice President of GeNO, commented, "We believe that this System offers the potential to provide PAH patients, as well as the clinicians that treat them, with a safe and effective diagnostic agent. We look forward to seeing the results of this study, and also to filing additional INDs and completing acute and chronic treatment studies. There is a well-established body of clinical evidence suggesting clinical benefit on the use of inhaled nitric oxide for patients with a variety of serious diseases, and the GeNO NITROSYL Systems would add a valuable option for clinicians treating these difficult conditions.  GeNO's system would help address cost, complexity and the lack of portability of current treatment regimens and potentially reach a much larger group of patients."

The next version of GeNO's platform to enter the clinic later this year will be the GeNO Ambulatory NITROSYL System, which is a hand-held unit with a disposable liquid source.  This portable unit snaps into a small, battery operated pump module attaching to a hip or arm holster and provides up to a 4-day continuous supply of inhaled nitric oxide for chronic use.  The simplicity and ease-of-use this system has the potential to greatly expand the use of inhaled nitric oxide to many new chronic indications.  

ABOUT GeNO LLC

GeNO LLC, founded in 2006, is a privately held, advanced development-stage technology company that is developing innovativ
'/>"/>

SOURCE GeNO LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK
2. Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
3. Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing
4. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
5. Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
6. Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
7. NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
8. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-111 and Herceptin in Patients with Advanced Her2 Positive Breast Cancer
9. Fibrocell Science, Inc. Initiates Histology Study of azficel-T
10. Chimerix Initiates Phase 1 Study of CMX157
11. Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... , May 5, 2015  23andMe, Inc., the ... the Lupus Research Study in collaboration with ... with systemic lupus erythematosus, more commonly known as lupus, ... of lupus. The effort is also in collaboration with ... Awareness Month in May. Approximately 1.5 million ...
(Date:5/5/2015)... Hayden-McNeil is pleased to announce they ... for smaller courses. This program is specifically designed for ... , “I’m very excited about offering our publishing ... said Jeff McCarthy, Hayden-McNeil president. “By working with more ... to make education both more effective and affordable.” , ...
(Date:5/5/2015)... Psyche Systems Corporation and Luminate Health have ... platform that helps labs comply with new federal HHS ... way patients engage with these results, and improves provider ... a HIPAA-compliant digital platform that gives labs an easy ... lab results, and uniquely connects labs, physicians, and patients ...
(Date:5/5/2015)... May 05, 2015 The Academy of ... of Indiana, led by Indiana Gov. Mike Pence, has ... AMA Foundation will host a Family Fest and aviation ... proceeds will benefit the Wounded Warrior Project. , National ... of Model Aeronautics—the country’s foremost organization for model aviation—to ...
Breaking Biology Technology:23andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 3Hayden-McNeil Expands Publishing Program to Service Lower Enrollment Courses 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 3State of Indiana proclaims August 15 as Model Aviation Day 2
... May 26, 2010 , , ... - Study Data Shows ORMD-0801 Resulted in Glucose and C-Peptide Reduction , ... Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) ( ... study to assess the safety and pharmacodynamics,of five oral insulin formulations in healthy subjects," ...
... 26 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, ... & Research Center at the University of Texas ... (CTRC) has started patient enrolment in a U.S. Phase ... combination with gemcitabine (Gemzar(R)) in patients with advanced pancreatic ...
... LONDON , May 26 ... announces the issuance of United States patent ... Treatment of Cancer and Other Neovascularization Disease, by the ... patent, which deepens the Company,s diverse portfolio of RNA ...
Cached Biology Technology:Oramed Pharmaceuticals Announces Publication of Research Article on its Oral Insulin Capsule ORMD-0801 in Diabetes, Obesity and Metabolism 2Oramed Pharmaceuticals Announces Publication of Research Article on its Oral Insulin Capsule ORMD-0801 in Diabetes, Obesity and Metabolism 3Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial 2Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial 3Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial 4Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States 2Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States 3Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States 4
(Date:4/9/2015)... Calif. , April 9, 2015 Synaptics ... interface solutions, announced today that it will report financial ... Thursday, April 23, 2015, after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:4/6/2015)... Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/143028 for MINIATURE, MULTI-PURPOSE ANTENNA ... NXT-ID introduces a new revolutionary method ... surrounds the use of miniature antenna modules for ...
(Date:4/2/2015)... April 2, 2015 At its 2015 ACMG ... City , the American College of Medical Genetics ... directors to its Board.  Members of the ACMG Board ... for forming and advancing its policies and programs. ACMG ... "It,s an eventful time in medical genetics ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... ago inhabited savannas -- grassy plains dotted with trees and ... earth science Naomi Levin of The Johns Hopkins University,s Krieger ... at odds with a theory which holds that these ... forth by prominent University of California at Berkeley researcher Tim ...
... The title sounds like a crime novel on a dime-store ... meaning. And the prime suspect is very, very small. ... that the first cells to starve in a slime mold seem ... reproduce, but also pushes those that keep on eating into sacrificing ...
... Climate change is about more than just polar ... whose research into climate change communication has been published ... the efforts of journalists, campaigners and politicians to engage ... ,visual strategies, can communicate climate change messages against a ...
Cached Biology News:Early human habitat was savanna, not forest 2A Dicty mystery solved 2Beyond polar bears? Experts look for a new vision of climate change to combat skepticism 2
...
... kit contains sufficient materials for 1,464 array sample elements. ... each , Blocker BSA in PBS ... Antibody, HRP-conjugated: 10 g , BupH ... 10% Tween-20: 2 x 10 ml ampules , ...
... Clean and Accurate Results Laser Capture ... the sensitivity and accuracy of molecular assays ... types and multi-cellular structures isolated from whole ... to microdissection-developed in 1996 at the National ...
Mouse monoclonal antibody raised against a partial recombinant DHX8. NCBI Entrez Gene ID = DHX8...
Biology Products: